Amgen’s Kyprolis wins ‘backbone therapy’ FDA nod after trumping Velcade in trial

Carly Helfand Back in March, Amgen's Kyprolis posted impressive results in a head-to-head trial with Takeda behemoth Velcade–and now, those results have helped it grab an ...

Shkreli’s 5th Amendment hall pass rejected for congressional drug pricing hearing

Emily Wasserman Pharma bro Martin Shkreli is requesting a hall pass to get out of testifying at a congressional hearing on drug pricing next week after receiving a subpoena ordering ...

Yes, Gilead put superhigh prices on hep C drugs, but what can you do? Senators ask

Eric Palmer After 18 months spent slicing and dicing 20,000 pages of Gilead Sciences documents and emails, a Senate investigation concluded that the drugmaker put very high price tags ...

Avanir Pharmaceuticals taps Rohan Palekar for CEO role

Alok Saboo In this week's Chutes and Ladders, Rohan Palekar was appointed CEO of Avanir Pharmaceuticals, Allan Shaw was named CFO at Syndax, and Dr. Craig Granowitz was named chief ...

Amgen’s Repatha wins first PCSK9 OK in Japan

Carly Helfand Amgen and the Sanofi and Regeneron team have been duking it out with their PCSK9 meds in the U.S., racing to ink payer deals in an effort to get ahead. But now, Amgen ...

Sanofi’s reportedly on the verge of ‘sizable’ job cuts as diabetes business sputters

Damian Garde French drugmaker Sanofi is soon to announce some "sizable" cuts to its payroll, according to Stat, part of new CEO Olivier Brandicourt's plot to engineer ...

Pfizer’s Ibrance clears first hurdle to early access in U.K.

Carly Helfand Pfizer's new cancer standout, Ibrance, has taken its first step toward joining the U.K.'s Early Access to Medicines program, winning the "promising innovative ...

CRISPR biotech Intellia leases a big R&D hub in Cambridge, MA

Damian Garde Intellia Therapeutics, a Novartis-backed biotech working on gene-editing technology, leased a sizable research space in the hotbed of Cambridge, MA. FierceBiotech News

Struggling XenoPort rumored to consider a sale

Damian Garde XenoPort, a month removed from deep job cuts, is looking to sell itself, according to Reuters, reaching out to potential acquirers after a string of R&D disappointments. FierceBiotech ...

GlaxoSmithKline bails on Basilea’s eczema drug, nixing a $72M payout

Damian Garde GlaxoSmithKline has abandoned its plot to win FDA approval for an eczema treatment from Basilea Pharmaceutica, ending a project that could have paid its partner about $ ...

U.K.’s NICE says yes to Opdivo for advanced skin cancer

Eric Palmer Last month the U.K. drug cost watchdog nixed Bristol-Myers Squibb's immunotherapy Opdivo for use against lung cancer, saying in draft guidance that it just cost too ...

Astellas is still struggling to close its $379M Ocata buyout

Damian Garde When Astellas signed a deal to acquire Ocata Therapeutics in November, it expected the company's shareholders to accept its $ 8.50-a-share offer within 20 days. But ...
Page 5 of 17« First...34567...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS